Dr. John Lucas brings over 24 years of experience in the biopharmaceutical industry. John is the former Chief Executive Officer of Oxford Cannabinoid Technologies based in the United Kingdom. John began his career in biopharma at Genset S.A. (Paris) and Genset Corporation (San Diego, California) where he served as Vice President, Worldwide Intellectual Property. He also held the position of Vice President, Intellectual Property at Transform Pharmaceuticals Inc. of Lexington Massachusetts, and at Metabasis Therapeutics Inc., a biopharmaceutical company in California.

John holds a law degree (JD) from George Washington University and a PhD in molecular genetics from Ohio State University. He also holds a Master’s in microbiology and a Bachelor of Education from Ohio University.

John moved to the United Kingdom at the end of 2007 as General Counsel and Vice President of Intellectual Property at Silence Therapeutics plc where he was responsible for a wide range of legal and business matters and played a key role in the corporate transaction with Intradigm Corporation. John then became Chief Executive Officer of Cizzle Biotechnology Limited, a company developing diagnostic tests for the detection of lung cancer. Other roles he has held include Head of Patents, Biosimilars, at Boehringer Ingelheim Pharma GmbH & Co. KG.